**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 55616

**Manuscript type:** ORIGINAL ARTICLE

***Observational Study***

**Awareness and attitude of fecal microbiota transplantation through transendoscopic enteral tubing among inflammatory bowel disease patients**

Zhong M *et al*.Patient’s attitude to fecal microbiota transplantation

Min Zhong, Yang Sun, Hong-Gang Wang, Cicilia Marcella, Bo-Ta Cui, Ying-lei Miao, Fa-Ming Zhang

**Min Zhong, Cicilia Marcella, Bo-Ta Cui, Fa-Ming Zhang,** Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, Jiangsu Province, China

**Min Zhong, Cicilia Marcella, Bo-Ta Cui, Fa-Ming Zhang,** Key Lab of Holistic Integrative Enterology, Nanjing Medical University, Nanjing 210011, Jiangsu Province, China

**Yang Sun, Ying-lei Miao,** Yunnan Institute of Digestive Disease, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan Province, China

**Hong-Gang Wang,** Medical Center for Digestive Diseases, The Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University, Huaian 223300, Jiangsu Province, China

**Author contributions:** Zhang F-m designed the study; Zhong M designed the survey and drafted the manuscript; Zhang F-m, Cui B-t and Marcella C were involved in revision of the manuscript; Zhong M, Sun Y, Wang H-g and Marcella C were responsible for the data acquisition; Zhong M conducted the statistical analyses.

**Supported by** Jiangsu Province Creation Team and Leading Talents project (to Zhang Fm).

**Corresponding author: Fa-ming Zhang, MD, PhD, Director, Professor,** Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, No. 121 Jiangjiayuan, Nanjing 210011, Jiangsu Province, China. fzhang@njmu.edu.cn

**Received:** March 26, 2020

**Revised:** April 28, 2020

**Accepted:** July 30, 2020

**Published online:** September 6, 2020

**Abstract**

BACKGROUND

Transendoscopic enteral tubing (TET) has been used in China as a novel delivery route for fecal microbiota transplantation (FMT) into the whole colon with a high degree of patient satisfaction among adults.

AIM

To explore the recognition and attitudes of FMT through TET in patients with inflammatory bowel disease (IBD).

METHODS

An anonymous questionnaire, evaluating their awareness and attitudes toward FMT and TET was distributed among IBD patients in two provinces of Eastern and Southwestern China. Question formats included single-choice questions, multiple-choice questions and sorting questions. Patients who had not undergone FMT were mainly investigated for their cognition and acceptance of FMT and TET. Patients who had experience of FMT, the way they underwent FMT and acceptance of TET were the main interest. Then all the patients were asked whether they would recommend FMT and TET. This study also analyzed the preference of FMT delivery in IBD patients and the patient-related factors associated with it.

RESULTS

A total of 620 eligible questionnaires were included in the analysis. The survey showed that 44.6% (228/511) of patients did not know that FMT is a therapeutic option in IBD, and 80.6% (412/511) of them did not know the concept of TET. More than half (63.2%, 323/511) of the participants stated that they would agree to undergo FMT through TET. Of the patients who underwent FMT *via* TET [62.4% (68/109)], the majority [95.6% (65/68)] of them were satisfied with TET. Patients who had undergone FMT and TET were more likely to recommend FMT than patients who had not (94.5% *vs* 86.3%, *p* = 0.018 and 98.5% *vs* 87.8%, *p* = 0.017). Patients’ choice for the delivery way of FMT would be affected by the type of disease and whether the patient had the experience of FMT. When compared to patients without experience of FMT, Crohn’s disease and ulcerative colitis patients who had experience of FMT preferred mid-gut TET (*p* < 0.001) and colonic TET (*p* < 0.001), respectively.

CONCLUSION

Patients’ experience of FMT through TET lead them to maintain a positive attitude towards FMT. The present findings highlighted the significance of patient education on FMT and TET.

**Key words:** Recognition; Fecal microbiota transplant; Washed microbiota transplantation; Transendoscopic enteral tubing; Attitude

Zhong M, Sun Y, Wang H-G, Marcella C, Cui B-T, Miao YL, Zhang F-M. Awareness and attitude of fecal microbiota transplantation through transendoscopic enteral tubing among inflammatory bowel disease patients. *World J Clin Cases* 2020; 8(17): 3786-3796 URL: <https://www.wjgnet.com/2307-8960/full/v8/i17/3786.htm> DOI: https://dx.doi.org/10.12998/wjcc.v8.i17.3786

**Core tip:** Fecal microbiota transplantation (FMT) has shown its therapeutic potential in inflammatory bowel disease. Transendoscopic enteral tubing (TET) has been used in China as a novel delivery route for FMT. Perception and attitude towards FMT and TET by physicians and patients play an important role in determining its acceptability. We investigated Chinese inflammatory bowel disease patients’ attitude towards FMT and TET and also examined their preference of FMT delivery. This is the first large-scale study of inflammatory bowel disease patients’ perceptions and attitude towards FMT and TET in an Asian country.

**INTRODUCTION**

The prevalence of inflammatory bowel disease (IBD) continues to increase steadily in Western countries and has a rapidly increasing incidence in China[1,2]. Fecal microbiota transplantation (FMT) has shown its therapeutic potential in IBD[3-6]. The rate of clinical response in randomized controlled trials involving FMT in ulcerative colitis (UC) ranged between 39% and 55%[6-9]. Since the first case of severe Crohn’s disease (CD) treated with FMT through the mid-gut[10], another large study has shown that multiple fresh FMTs were effective to induce and maintain clinical remission in CD with intraabdominal inflammatory mass[4]. The concept of FMT was traced back in China to at least 1700 years ago[11] in which the gut microbiota was transferred from healthy people to the patients to treat dysbiosis related diseases[12], such as metabolic syndrome[13], gut-brain axis-related diseases[14] and even hypertension[15]. However, the efficacy and safety reports by different research centers varied due to many reasons including the methodology of preparation of fecal microbiota and the delivery way of FMT[3,6,16]. These controversial reports might be the evidence for questioning the scientific basis of gut microbiome studies and criticizing that many of them are farfetched[17]. Therefore, the useful delivery of microbiota to gut is the core issue to result in the real efficacy of FMT.

Ding *et al*[3] reported that a lower rate of FMT-related adverse events was found in patients with colonic transendoscopic enteral tubing (TET) as the delivery method. TET is the latest progression on FMT delivery way, including the mid-gut/naso-jejunal TET and colonic TET[18,19]. The tiny colonic TET tube is fixed onto the wall by clips after it is inserted into the cecum through the endoscopic channel. It has been a safe and convenient procedure for multiple FMTs and colonic medication administration with a high degree of satisfaction among adult patients[3,18].

A new clinical therapeutic application depends not only on its efficacy but also on the recognition and attitudes of physicians and patients. Ren *et al*[20] reported that Chinese physicians have a high awareness and acceptance of FMT, and one of the physicians’ greatest concerns was patient acceptability. Previous studies in our center have shown that the clinical efficacy of FMT maintains a positive attitude among CD patients[21]. However, there has been no large-scale survey that focuses on the recognition and attitude of IBD patients toward FMT and TET in China. This survey aimed to demonstrate the current attitudes of Chinese IBD patients toward FMT through TET and further provide recommendations for physicians.

**MATERIALS AND METHODS**

***Study design, setting and participants***

A questionnaire survey among the IBD patients were conducted in three centers, including the Second Affiliated Hospital of Nanjing Medical University, the Affiliated Huaian No. 1 People’s Hospital of Nanjing Medical University and the First Affiliated Hospital of Kunming Medical University. Questionnaires were distributed by electronic form to 652 patients from April 2019 to November 2019. They completed the questionnaires voluntarily under anonymous and uncompensated conditions. In this article, we use ‘patients’ and ‘participants’ interchangeably to refer to the respondents. This study was approved by the institutional ethical review board.

***Questionnaire design***

An anonymous questionnaire was developed according to our experiences in performing FMT and TET (partially detailed in Supplementary Table 1). Question format included single choice, multiple choice and sorting questions. After the questions on patients’ demographics (age, gender, *etc*), and disease characteristics (disease category, self-reported disease severity, *etc*), patients were asked about the experience of FMT. In particular, the participants were divided into two groups: (1) Group 1: patients without experience of FMT; and (2) Group 2: patients with experience of FMT. The flow chart of the questionnaire is shown in Figure 1.

***Statistical analysis***

Data collection and its statistical analysis were carried out using the SPSS software system (SPSS for Windows, Version 23.0, SPSS Inc., Chicago, IL, United States). The general knowledge and attitude towards the FMT and TET were compared with the use of multivariate analysis, Pearson Chi-square test or Fisher’s exact test. Qualitative variables were expressed as percentages, whereas quantitative variables were expressed as a median. For all analyses, *p* < 0.05 was considered statistically significant.

**Results**

***Patients’ characteristics***

In total, 652 surveys were returned and 620 were qualified for analysis (32 questionnaires with missing items) yielding an effective rate of 95.1%. Patients’ ranged in age from 14 years to 76 years (median: 35 years), and 30 patients were below 18-years-old at the time of the study (completed under parents’ guidance). Among them, 109 (17.6%) patients had undergone FMT (Table 1).

***Questions on fecal microbiota transplant***

Nearly half of participants (44.6%, 228/511) with no experience of FMT were unaware of FMT. Of them, CD patients (144/211) showed significantly higher awareness of FMT when compared to UC patients (115/260) (*p* = 0.012, odds ratio (OR) = 0.369, 95% confidence interval (CI): 0.25-0.54). Figure 2A showed the different approaches for patients to learn about FMT. Mass media (36.2%) and physician’s recommendation (21.1%) were the most common sources of information. In all, 61.5% of patients (314/511) supported FMT based on their current state of knowledge, whereas 35.6% (182/511) were not sure about it. The main reasons for patients supporting FMT or not were displayed in Figure 3A and 3B. UC patients showed a higher percentage of willingness to undergo FMT than CD patients (51.9% *vs* 39.2%, *p* = 0.03). No other significant difference was found based on gender, disease category, level of education, medical professional, family history of IBD or disease severity.

In the present study, 86.3% (441/511) of the patients agreed to recommend FMT as a treatment for IBD to others. Whereas, the relevant analysis showed that patients in Group 2 were more likely to recommend FMT than those in Group 1 (94.5% *vs* 86.3%, *p* = 0.018). Multivariate analysis showed that no significant difference was observed in gender (male *vs* female), disease category (CD *vs* UC) and disease severity (mild *vs* severe) parameters. In addition, patients who had undergone TET showed a more positive attitude toward FMT than patients who never underwent TET (98.5% *vs* 87.8%, *p* = 0.017).

***Questions on the delivery of fecal microbiota transplantation***

Up to 80.6% (412/511) of the patients in Group 1 were unaware of TET prior to this survey. The first approach for them to learn about TET is shown inFigure 2B. More than half (63.2%, 323/511) of the participants stated that they would agree to undergo FMT through TET. When comparing male *versus* female (OR = 0.769, 95%CI: 0.512-1.157, *p* = 0.208), CD *versus* UC (OR = 1.378, 95%CI: 0.926-2.051, *p* = 0.114), patients with mild *versus* severe disease (OR = 0.959, 95%CI: 0.720-1.278, *p* = 0.775), the differences were not significant.

Among the five options offered: gastroscopy, colonoscopy, mid-gut TET, colonic TET and enema, the patients were further asked which transplant route they preferred. In patients of Group 1, 216/511(42.3%) of the participants preferred enema, while 31.2% of the participants were more likely to choose gastroscopy in Group 2, with a significant difference between the two groups (*p* < 0.001). If we focus on the choice of TET, CD patients in Group 2 were more likely to choose mid-gut TET than patients in Group 1 (29.0% *vs* 13.3%, *p* < 0.001) (Figure 4A). Meanwhile, for UC patients, Group 2 had a larger proportion of patients who preferred colonic TET than Group 1 (42.5% *vs* 25.4%, *p* < 0.001) (Figure 4B).

In terms of the willingness to recommend TET, 82.7% (513/620) of patients were willing to recommend it, and there was a significant difference in type of disease (*p* = 0.022) and gender (*p* = 0.047). A multivariate analysis showed that the type of disease (OR = 0.614, 95%CI: 0.423-0.891, *p* = 0.01) was an independent factor influencing the recommendations. UC patients were more likely to recommend TET than CD patients (50.7% *vs* 41.5%, *p* =0.01).

**Discussion**

This study delineated that nearly half of IBD patients were unaware that FMT is a therapeutic option, and a large proportion of patients did not know the concept of TET prior to this survey. Overall, the results indicated a poor recognition of FMT and TET amongst IBD patients in China. This finding was in line with the survey conducted in Switzerland and the United States that revealed the poor recognition of FMT in IBD patients[22,23]. The reasons that IBD patients have a low awareness of FMT and TET need to be explored. FMT is a relatively new technique and has only been written into the guidelines for the treatment of recurrent *Clostridium difficile* infection since 2013[24]. TET is also a new interventional method, which was first published in 2016[18] and only used in some hospitals in China mainland[25,26,27] and China Taiwan[28] up to 2019.

The results suggest that mass media and physician’s recommendation are the most common approaches for patients to learn about FMT and TET. Although mass media is a powerful way to disseminate knowledge, the coverage of this emerging therapy is limited with varying degrees of depth and attention. It is hard to make sure patients do not receive misleading information from mass media. This may explain why the cognition of FMT among IBD patients has not improved significantly in recent years[22,23]. Chinese clinicians who have a negative attitude toward media that exaggerate and mystify the effects of FMT as “magic” and “miraculous” fear that this may mislead patients[29]. Another survey showed that the physician’s perceptions of FMT can indirectly affect patient’s acceptance[23]. The approach of physician’s recommendation will be more effective in improving patient’s cognition on FMT and TET than mass media in the future.

In previous studies, the stigma or “yuck” factor associated with FMT and the lack of evidence on the safety and efficacy of FMT have affected patients’ interest in this therapy[22,23]. However, many studies have demonstrated that FMT is a safe and promising therapy for IBD[3,4,7]. Since 2014, the methodology of FMT preparation in our group was different from the traditional manual FMT. The new methodology of FMT was recently coined as washed microbiota transplantation (WMT), which is dependent on the automatic facilities and washing process in a laboratory room with biosafety level 3[30]. It was demonstrated that WMT is better than the manual preparation of FMT in improving safety, enriching the precise amount of microbiota and improving quality control in practice[30,31]. WMT has been used in China in most of the microbiota therapy centers and the methodology was released by the consensus statement from the FMT-standardization Study Group in 2019[31]. In addition, patients may refuse to undergo FMT repeatedly in a short time because of repeated endoscopic procedures and bowel preparation, but the effectiveness from a single FMT might be limited in severe and refractory microbiota-related conditions. TET can solve the limitations of repeating FMT in a short time, avoiding intestinal injury and bleeding caused by repeated insertion of the enema tube or colonoscopy. Patients in the present study showed a great interest in TET.

The present study demonstrated that patient’s attitude towards FMT would be influenced by the FMT and TET experience of a patient. The patients who had experience of FMT and TET exhibited more positive attitudes toward FMT and were more likely to recommend FMT. Undergoing FMT through TET may improve the understanding of FMT and eliminate patients’ concerns about the aesthetics of FMT. Patients’ choice for the delivery of FMT was influenced by the type of disease and whether the patient had undergone FMT. Patients with experience of FMT were more willing to choose TET as the preferred route. UC patients preferred colonic TET and CD patients preferred mid-gut TET. The reason for this difference could be, other than FMT administration, that the TET tube could be useful in giving enteral nutrition for CD patients through mid-gut TET, while UC patients benefited by whole-colon medication administrations *via* colonic TET.

There is no single best universal delivery that matches all patients, but the efficacy and safety should be the most important considerations when choosing the delivery method. For example, capsulized microbiota is convenient for adults and *Clostridium difficile* infection but not for children and IBD, especially for children diagnosed with autism. When considering the delivery route of FMT, disease condition, aesthetic factors, psychology and privacy should be considered carefully during the entire workflow. The researchers and practitioners must pay attention to when the improper delivery caused the negative results, which could increase the medical cost, social cost related to the disease treatment and misleading from patients and medical research.

The long-standing goals of our team are to promote the development of FMT and FMT-related technologies. It can provide recommendations for us to move standardized FMT by understanding patients’ perspectives of FMT and TET, thus bringing benefits to more patients. There are several limitations in this study. The participants we surveyed were from Jiangsu and Yunnan province, which might not be representative of all populations. A larger sample is necessary for future research. The current findings might be unsuitable to draw conclusions on the patients’ attitude to WMT.

In conclusion, this study showed the significance of education to patients due to low awareness or knowledge of FMT. TET as a novel delivery route of FMT needs increasing attention. If the awareness about FMT and TET is increased, then more positive attitudes will be exhibited toward FMT. Therefore, it is important to determine the knowledge, attitude and preferences of patients for FMT though TET. This study indicates that better education for patients should promote the development of FMT.

**Article Highlights**

***Research background***

Fecal microbiota transplantation (FMT) has shown its therapeutic potential in inflammatory bowel disease (IBD). Transendoscopic enteral tubing (TET) has been used in China as a safe and convenient procedure for multiple FMTs and colonic medication administration with a high degree of satisfaction among adult patients.

***Research motivation***

A new clinical therapeutic application depends not only on its efficacy but also on the recognition and attitudes of physicians and patients.

***Research objectives***

The main objectives of this study were to explore the recognition and attitudes of FMT through TET in patients with IBD and the preference of FMT delivery.

***Research methods***

An anonymous questionnaire was distributed among IBD patients in two provinces of Eastern and Southwestern China. The participants were divided into two groups: (1) Group 1: patients without experience of FMT; and (2) Group 2: patients with experience of FMT. We also evaluated their awareness and attitudes toward FMT and TET and their preference of FMT delivery.

***Research results***

Nearly half of the IBD patients were unaware that FMT was a therapeutic option, and a large proportion of patients did not know the concept of TET prior to this survey. Mass media and physician’s recommendation were the most common sources of information. Patients’ choice for the delivery of FMT was affected by the type of disease and whether the patient had experience with FMT. Crohn’s disease patients in Group 2 were more likely to choose mid-gut TET than patients in Group 1. Meanwhile, for ulcerative colitis patients, Group 2 had a larger proportion of patients who preferred colonic TET than Group 1. The relevant analysis showed that patients in Group 2 were more likely to recommend FMT than those in Group 1. The type of disease was an independent factor influencing the recommendations of TET. Ulcerative colitis patients were more likely to recommend TET than Crohn’s disease patients.

***Research conclusions***

IBD patients have a low awareness of FMT and TET in China. If awareness about FMT and TET increases, then a more positive attitude will be exhibited toward FMT, thus showing the significance of education to patients.

***Research perspectives***

Further studies need to clarify the patients’ attitude to the washed microbiota transplantation, which has been regarded as the new technology of TET.

**ACKNOWLEDGMENTS**

The authors would like to thank all the participants for who voluntarily participated in the survey for their time and efforts. The authors also thank Ms. Heena Buch for her careful language assistance.

**References**

1 **Kaplan GG**, Ng SC. Understanding and Preventing the Global Increase of Inflammatory Bowel Disease. *Gastroenterology* 2017; **152**: 313-321.e2 [PMID: 27793607 DOI: 10.1053/j.gastro.2016.10.020]

2 **Ng SC**, Bernstein CN, Vatn MH, Lakatos PL, Loftus EV Jr, Tysk C, O'Morain C, Moum B, Colombel JF; Epidemiology and Natural History Task Force of the International Organization of Inflammatory Bowel Disease (IOIBD). Geographical variability and environmental risk factors in inflammatory bowel disease. *Gut* 2013; **62**: 630-649 [PMID: 23335431 DOI: 10.1136/gutjnl-2012-303661]

3 **Ding X**, Li Q, Li P, Zhang T, Cui B, Ji G, Lu X, Zhang F. Long-Term Safety and Efficacy of Fecal Microbiota Transplant in Active Ulcerative Colitis. *Drug Saf* 2019; **42**: 869-880 [PMID: 30972640 DOI: 10.1007/s40264-019-00809-2]

4 **He Z**, Li P, Zhu J, Cui B, Xu L, Xiang J, Zhang T, Long C, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass. *Sci Rep* 2017; **7**: 4753 [PMID: 28684845 DOI: 10.1038/s41598-017-04984-z]

5 **Cui B**, Feng Q, Wang H, Wang M, Peng Z, Li P, Huang G, Liu Z, Wu P, Fan Z, Ji G, Wang X, Wu K, Fan D, Zhang F. Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. *J Gastroenterol Hepatol* 2015; **30**: 51-58 [PMID: 25168749 DOI: 10.1111/jgh.12727]

6 **Cold F**, Browne PD, Günther S, Halkjaer SI, Petersen AM, Al-Gibouri Z, Hansen LH, Christensen AH. Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated - an open-label pilot study. *Scand J Gastroenterol* 2019; **54**: 289-296 [PMID: 30946615 DOI: 10.1080/00365521.2019.1585939]

7 **Moayyedi P**, Surette MG, Kim PT, Libertucci J, Wolfe M, Onischi C, Armstrong D, Marshall JK, Kassam Z, Reinisch W, Lee CH. Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. *Gastroenterology* 2015; **149**: 102-109.e6 [PMID: 25857665 DOI: 10.1053/j.gastro.2015.04.001]

8 **Rossen NG**, Fuentes S, van der Spek MJ, Tijssen JG, Hartman JH, Duflou A, Löwenberg M, van den Brink GR, Mathus-Vliegen EM, de Vos WM, Zoetendal EG, D'Haens GR, Ponsioen CY. Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis. *Gastroenterology* 2015; **149**: 110-118.e4 [PMID: 25836986 DOI: 10.1053/j.gastro.2015.03.045]

9 **Costello SP**, Hughes PA, Waters O, Bryant RV, Vincent AD, Blatchford P, Katsikeros R, Makanyanga J, Campaniello MA, Mavrangelos C, Rosewarne CP, Bickley C, Peters C, Schoeman MN, Conlon MA, Roberts-Thomson IC, Andrews JM. Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. *JAMA* 2019; **321**: 156-164 [PMID: 30644982 DOI: 10.1001/jama.2018.20046]

10 **Zhang FM**, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. *World J Gastroenterol* 2013; **19**: 7213-7216 [PMID: 24222969 DOI: 10.3748/wjg.v19.i41.7213]

11 **Zhang F**, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation? *Am J Gastroenterol* 2012; **107**: 1755; author reply p.1755-1755; author reply p.1756 [PMID: 23160295 DOI: 10.1038/ajg.2012.251]

12 **Cui B**, Li P, Xu L, Peng Z, Xiang J, He Z, Zhang T, Ji G, Nie Y, Wu K, Fan D, Zhang F. Step-up fecal microbiota transplantation (FMT) strategy. *Gut Microbes* 2016; **7**: 323-328 [PMID: 26939622 DOI: 10.1080/19490976.2016.1151608]

13 **Wang PX**, Deng XR, Zhang CH, Yuan HJ. Gut microbiota and metabolic syndrome. *Chin Med J (Engl)* 2020; **133**: 808-816 [PMID: 32106124 DOI: 10.1097/CM9.0000000000000696]

14 **Sun LJ**, Li JN, Nie YZ. Gut hormones in microbiota-gut-brain cross-talk. *Chin Med J (Engl)* 2020; **133**: 826-833 [PMID: 32132364 DOI: 10.1097/CM9.0000000000000706]

15 **Liu Y**, Zhang FM, Hu WZ. Hypertension: microbiota-targeting treatment. *Chin Med J (Engl)* 2020; **133**: 1353-1354 [PMID: 31977554 DOI: 10.1097/CM9.0000000000000657]

16 **Paramsothy S**, Kamm MA, Kaakoush NO, Walsh AJ, van den Bogaerde J, Samuel D, Leong RWL, Connor S, Ng W, Paramsothy R, Xuan W, Lin E, Mitchell HM, Borody TJ. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet* 2017; **389**: 1218-1228 [PMID: 28214091 DOI: 10.1016/S0140-6736(17)30182-4]

17 **Li D**, Gao C, Zhang F, Yang R, Lan C, Ma Y, Wang J. Seven facts and five initiatives for gut microbiome research. *Protein Cell* 2020; **11**: 391-400 [PMID: 32172500 DOI: 10.1007/s13238-020-00697-8]

18 **Peng Z**, Xiang J, He Z, Zhang T, Xu L, Cui B, Li P, Huang G, Ji G, Nie Y, Wu K, Fan D, Zhang F. Colonic transendoscopic enteral tubing: A novel way of transplanting fecal microbiota. *Endosc Int Open* 2016; **4**: E610-E613 [PMID: 27556065 DOI: 10.1055/s-0042-105205]

19 **Long C**, Yu Y, Cui B, Jagessar SAR, Zhang J, Ji G, Huang G, Zhang F. A novel quick transendoscopic enteral tubing in mid-gut: technique and training with video. *BMC Gastroenterol* 2018; **18**: 37 [PMID: 29534703 DOI: 10.1186/s12876-018-0766-2]

20 **Ren RR**, Sun G, Yang YS, Peng LH, Wang SF, Shi XH, Zhao JQ, Ban YL, Pan F, Wang XH, Lu W, Ren JL, Song Y, Wang JB, Lu QM, Bai WY, Wu XP, Wang ZK, Zhang XM, Chen Y. Chinese physicians' perceptions of fecal microbiota transplantation. *World J Gastroenterol* 2016; **22**: 4757-4765 [PMID: 27217707 DOI: 10.3748/wjg.v22.i19.4757]

21 **Xu L**, Zhang T, Cui B, He Z, Xiang J, Long C, Peng Z, Li P, Huang G, Ji G, Zhang F. Clinical efficacy maintains patients' positive attitudes toward fecal microbiota transplantation. *Medicine (Baltimore)* 2016; **95**: e4055 [PMID: 27472679 DOI: 10.1097/MD.0000000000004055]

22 **Kahn SA**, Vachon A, Rodriquez D, Goeppinger SR, Surma B, Marks J, Rubin DT. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. *Inflamm Bowel Dis* 2013; **19**: 1506-1513 [PMID: 23624888 DOI: 10.1097/MIB.0b013e318281f520]

23 **Zeitz J**, Bissig M, Barthel C, Biedermann L, Scharl S, Pohl D, Frei P, Vavricka SR, Fried M, Rogler G, Scharl M. Patients' views on fecal microbiota transplantation: an acceptable therapeutic option in inflammatory bowel disease? *Eur J Gastroenterol Hepatol* 2017; **29**: 322-330 [PMID: 27879485 DOI: 10.1097/MEG.0000000000000783]

24 **Surawicz CM**, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. *Am J Gastroenterol* 2013; **108**: 478-98; quiz 499 [PMID: 23439232 DOI: 10.1038/ajg.2013.4]

25 **Ding X**, Li Q, Li P, Chen X, Xiang L, Bi L, Zhu J, Huang X, Cui B, Zhang F. Fecal microbiota transplantation: A promising treatment for radiation enteritis? *Radiother Oncol* 2020; **143**: 12-18 [PMID: 32044171 DOI: 10.1016/j.radonc.2020.01.011]

26 **Xie WR**, Yang XY, Xia HH, Wu LH, He XX. Hair regrowth following fecal microbiota transplantation in an elderly patient with alopecia areata: A case report and review of the literature. *World J Clin Cases* 2019; **7**: 3074-3081 [PMID: 31624757 DOI: 10.12998/wjcc.v7.i19.3074]

27 **Huang HL**, Chen HT, Luo QL, Xu HM, He J, Li YQ, Zhou YL, Yao F, Nie YQ, Zhou YJ. Relief of irritable bowel syndrome by fecal microbiota transplantation is associated with changes in diversity and composition of the gut microbiota. *J Dig Dis* 2019; **20**: 401-408 [PMID: 31070838 DOI: 10.1111/1751-2980.12756]

28 **Wang JW**, Wang YK, Zhang F, Su YC, Wang JY, Wu DC, Hsu WH. Initial experience of fecal microbiota transplantation in gastrointestinal disease: A case series. *Kaohsiung J Med Sci* 2019; **35**: 566-571 [PMID: 31197926 DOI: 10.1002/kjm2.12094]

29 **Ma Y**, Yang J, Cui B, Xu H, Xiao C, Zhang F. How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study. *BMC Med Ethics* 2017; **18**: 39 [PMID: 28569156 DOI: 10.1186/s12910-017-0200-2]

30 **Zhang T**, Lu G, Zhao Z, Liu Y, Shen Q, Li P, Chen Y, Yin H, Wang H, Marcella C, Cui B, Cheng L, Ji G, Zhang F. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. *Protein Cell* 2020; **11**: 251-266 [PMID: 31919742 DOI: 10.1007/s13238-019-00684-8]

31 **Fecal Microbiota Transplantation-standardization Study Group**. Nanjing consensus on methodology of washed microbiota transplantation. *Chin Med J* 2020 [PMID: 32701590 DOI:10.1097/CM9.0000000000000954]

**Footnotes**

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of The Second Affiliated Hospital of Nanjing Medical University.

**Informed consent statement:** The study was a survey of patients’ perceptions using questionnaires. Patients were asked if they would like to complete the questionnaire before starting to fill it out. They would only complete the questionnaire if they wanted to. There was no risk to the participants, and no individual patient information was revealed under the condition of anonymity.

**Conflict-of-interest statement:** Zhang F-m invented the concept of transendoscopic enteral tubing and related devices. All other authors declare that they have no competing interests.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement checklist of items and the manuscript was prepared and revised accordingly.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** March 26, 2020

**First decision:** April 26, 2020

**Article in press:** July 30, 2020

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Santivañez J, Serban ED **S-Editor:** Gong ZM **L-Editor:** Filipodia **E-Editor:** Xing YX

**Figure legends**



**Figure 1 Flow chart of the study.** FMT: fecal microbiota transplantation; TET: Transendoscopic enteral tubing.

**图片包含 游戏机, 文字

描述已自动生成**

**Figure 2 Approaches to learn about fecal microbiota transplantation and transendoscopic enteral tubing for the first time.** A, B: All respondents’ approaches to primarily knowing about fecal microbiota transplantation (A) and transendoscopic enteral tubing (B) in patients without experience of fecal microbiota transplantation.

手机屏幕截图

描述已自动生成

**Figure 3 Reasons for supporting fecal microbiota transplantation (A) and not supporting fecal microbiota transplantation (B).**

图片包含 游戏机

描述已自动生成

**Figure 4 Optimal methods of undergoing** **fecal microbiota transplantation.** A:The preferred delivery of Crohn’s disease patients with and without experience of fecal microbiota transplantation; B: The preferred delivery way of ulcerative colitis patients with and without experience of fecal microbiota transplantation. FMT: fecal microbiota transplantation; TET: Transendoscopic enteral tubing.

**Table 1 Characteristics of the participants**

|  |  |  |
| --- | --- | --- |
| **Items** | **Result** | |
| **Group 1** | **Group 2** |
| Total number | 511 | 109 |
| Age, median (range), yr | 45.0 (35.5-51.0) | 35.0 (29.0-42.0) |
| Age at diagnosis, median (range), yr | 28.5 (21.0-38.0) | 26.0 (29.0-33.0) |
| Duration of disease, median (range), yr | 3.0 (1.5-7.5) | 8.0 (5.0-12.0) |
| Sex, male, *n* (%) | 326 (63.8) | 68 (62.4) |
| Disease category, *n* (%) |  |  |
| UC | 260 (50.9) | 40 (36.7) |
| CD | 211 (41.3) | 62 (56.9) |
| IBD unclassified | 40 (7.8) | 7 (6.4) |
| Level of education, *n* (%) |  |  |
| At or below primary school | 51 (10.0) | 6 (5.5) |
| Middle school or equivalent | 188 (36.8) | 35 (32.1) |
| At or above undergraduate | 272 (52.2) | 68 (62.4) |
| Medicine education background, *n* (%) |  |  |
| With | 48 (9.4) | 6 (5.5) |
| Without | 463 (90.6) | 103 (94.5) |
| Family history of IBD, *n* (%) |  |  |
| Yes | 38 (7.4) | 9 (8.3) |
| No | 473 (92.6) | 100 (91.7) |
| Self-reported disease severity, *n* (%) |  |  |
| Mild | 194 (38.0) | 36 (33.0) |
| Moderate | 248 (48.5) | 49 (45.0) |
| Severe | 69 (13.5) | 24 (22.0) |

CD: Crohn’s disease; FMT: fecal microbiota transplantation; IBD: inflammatory bowel disease; UC: Ulcerative colitis.